# Clinical efficacy and safety of icaritin in patients with hepatocellular carcinoma: a real-world study

## TL;DR

This study shows that icaritin, a natural compound, is effective and safe for treating advanced liver cancer in patients who can't have standard treatments.

## Contribution

The study provides real-world evidence of icaritin's efficacy and safety in treating unresectable hepatocellular carcinoma.

## Key findings

- Icaritin combination therapy showed higher disease control and survival rates compared to monotherapy.
- Icaritin treatment maintained quality of life and had minimal severe side effects.
- A patient achieved complete response with icaritin monotherapy, with prolonged progression-free survival.

## Abstract

Icaritin, a natural compound extracted from Epimedium, has demonstrated efficacy and a favorable safety profile in treating hepatocellular carcinoma (HCC), providing an option for patients intolerant to conventional treatment. However, real-world data remain limited. To assess the therapeutic potential and safety of icaritin for patients with unresectable HCC (uHCC), we conducted a retrospective analysis at our center.

This study analyzed 26 HCC patients treated with icaritin-based regimens (monotherapy, n = 10; combination therapy, n = 16) at Nanfang Hospital (June 2018–June 2024). We evaluated efficacy outcomes, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS), as well as safety and health-related quality of life (HRQOL).

The monotherapy group showed a DCR of 60.0%, median PFS of 3.5 months, and a median OS of 9.4 months. The combination therapy group had a DCR of 93.8%, a median PFS of 5.7 months, and a median OS of 10.6 months. The incidence of Grade 3 treatment-related adverse events (TRAEs) was 13.9%, and no Grade 4+ TRAEs were observed. HRQOL was maintained throughout treatment in either group. One patient with BCLC stage C achieved a partial response after 2 months of icaritin monotherapy and a complete response after 8 months, with PFS exceeding 18 months.

Icaritin-based therapy has certain efficacy and a favorable safety in uHCC, suggesting a therapeutic alternative for uHCC patients ineligible for standard treatments.